Dược Hậu Giang (DHG) reported third-quarter 2026 after-tax profit down 53% to 98.5 billion VND, its lowest quarterly level since Q1 2011, as net revenue fell 11% to over 1,023 billion VND and selling expenses rose 23%. The company said some operating costs and corporate income tax increased, including the impact of global minimum tax rules. For the first nine months, net revenue grew nearly 2% to 3,584 billion VND and pre-tax profit reached 839 billion VND, or 83.3% of the full-year pre-tax target of 1,007 billion VND. As of 30 September 2026, total assets were down about 15% from the start of the year, with short-term financial investments down by over 1,021 billion VND. Financing outflows of over 1,307 billion VND mainly reflected the cash payment of the 2025 dividend at a 100% rate.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Dược Hậu Giang (DHG) báo lãi quý III thấp nhất trong hơn 15 năm
Keywords
pharmaceuticalsearningsdividends
Open a keyword to see other news on the same topic.
Related news
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
- 3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
The article argues that Pfizer, T. Rowe Price and Verizon look undervalued because the market is overreacting to their headwinds, while the S&P 500 trades at 23.5 times earnings with a 1.1% yield. Pfizer trades at 9.6 times forward earnings and offers a 5.6% dividend yield with a payout ratio just under 60%, though revenue and earnings have declined since 2022 and patent expirations such as Eliquis are pressuring shares. T. Rowe Price has a 5% forward dividend yield, a 40-year record of consecutive dividend growth and trades at 10 times forward earnings, and its pivot toward ETFs could soften the impact of a market downturn. Verizon added 550,000 net customer additions in mobility and broadband in the second quarter of 2026, but its shares have slumped on concerns about SpaceX's satellite services, and it has a 6.2% forward dividend yield at less than 9 times forward earnings.
- Should You Buy CVS Health Stock While It's Under $100?
CVS Health, a pharmacy retailer with the Aetna insurance business, is up around 17% this year versus about 12% for the S&P 500, after earlier reaching highs of more than $110. When it last reported in August, revenue rose more than 7% to $106.1 billion, and the company raised its 2026 diluted EPS forecast to $6.84–$7.04 from $6.24–$6.44, following diluted EPS of $1.39 in 2025 that was weighed by goodwill impairment charges. The stock trades at a forward P/E of about 11 versus 19 for the S&P 500 and yields 2.9%. The author views the stock as well priced and says it could move back above $100, citing improved results and its yield. The latest earnings are due Nov. 4.
- Bristol Myers Squibb: Bargain Buy or Value Trap?
Bristol Myers Squibb (BMY) has a market cap of about $125 billion, but its stock has returned just 6% over five years, while the S&P 500 returned nearly 70%. In the first six months, legacy portfolio revenue fell 6% excluding FX, while the growth portfolio grew 12% organically; overall revenue rose just 3% organically. The stock is up nearly 14% this year, slightly ahead of the S&P 500's roughly 12%. It trades at about nine times estimated future earnings versus the S&P 500's average of 19, and pays a 4.1% dividend with a payout ratio of around 55%. The author views the stock as undervalued, while acknowledging the company is dealing with patent expirations.
- Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
Citadel Advisors, the hedge fund led by billionaire Ken Griffin, has been increasing its stake in AbbVie (ABBV) in recent months. In the second quarter, Citadel bought 2.7 million shares at an average price of $234.57, for about $633 million, bringing its holding to 3.2 million shares worth $909 million at the current price of about $284. The stock has risen about 24% this year and trades at 74 times trailing earnings, which some investors may view as expensive. The article's author nonetheless sees merit in AbbVie as a Dividend King that has raised its annual dividend for 50 consecutive years, currently $6.92 per share, a 2.43% dividend yield. The company has a strong brand lineup including Skyrizi, Rinvoq, Humira and Botox, and about 90 drugs and treatments in development; the FDA approved its once-daily Parkinson's pill Juvmo in September, and William Blair analysts expect its sales could reach as much as $1.4 billion annually by 2040. Of the 30 analysts tracked by Yahoo Finance, 24 rate the stock 'strong buy' or 'buy'.
Related markets
Latest news
- Sister of Novaland Chairman registers to buy 30 million NVL shares
Bui Cao Ngoc Quynh, sister of Novaland's Chairman, registered to buy 30 million NVL shares for trading expected from 2 to 13 November 2026, which would raise her holding from over 8.31 million shares (0.346%) to 38.31 million (1.594% of charter capital). Earlier, on 20 October, Diamond Properties, an organization related to the Chairman, registered to buy 7 million shares. Conversely, some executives registered to sell for personal reasons, including Mr. Duong Van Bac with over 10.63 million shares and Ms. Tran Thi Thanh Van and Mr. Cao Tran Duy Nam with about 7.58 million shares each. Novaland is also offering about 800 million shares to existing shareholders at VND 10,000 per share under a 3:1 rights ratio, with the rights transfer deadline extended to 23 November and the payment deadline to 26 November 2026.
- Bitcoin nears $81,000 ahead of Fed decision as ZEC jumps 8%
Bitcoin rose nearly 2% to just under $81,000 in Wednesday's Asian morning session, recovering from a weekend dip to nearly $79,000 as traders awaited the Federal Reserve's rate decision. Among major cryptocurrencies, ZEC led with an 8% jump to about $1,320, HYPE gained nearly 5%, and XRP and DOGE rose roughly 3%. Galaxy said Bitcoin's bear market likely ended in June, when it traded below $58,000, and that the asset is now in an accumulation phase, citing its return above the 50-week moving average, lighter selling pressure and rising U.S. debt. Traders will watch Fed Chair Kevin Warsh's press conference for hints of a December rate hike, while a daily close above $82,500 could signal the recovery is gaining momentum.
- Brands turning strength into action pull ahead in Interbrand's Best Global Brands 2026
Interbrand's Best Global Brands 2026 ranking puts total brand value at $3.87 trillion, up 8.1% from $3.58 trillion in 2025. Technology remains the biggest driver of value creation, with Nvidia entering the global Top 10 and increasing its brand value by more than 71%, the fastest growth in this year's ranking, while Google climbed to No. 3. Entertainment overtook Automotive as the second most valuable sector, while Automotive recorded the sharpest decline, and new entrants include Zurich, Hitachi, GE Healthcare and Hewlett Packard Enterprise. Interbrand's Global CEO Gonzalo Brujó said strong reputation alone is no longer enough, and that the brands pulling ahead use “brand” as a business tool to create new demand and grow.
- VIB posts nearly VND 7,600 billion in 9-month profit, continues to improve operating efficiency
VIB reported nine-month 2026 profit before tax of nearly VND 7,600 billion, up 8% year on year, with total operating income of over VND 17,300 billion, up 18%, while operating expenses fell 2% to over VND 5,300 billion. By the end of September, total assets reached nearly VND 600 trillion, up 8% from the start of the year; outstanding credit rose 8% to over VND 411 trillion and customer deposits rose 9% to over VND 322 trillion. The bank set aside over VND 4,300 billion in credit risk provisions, kept its NPL ratio at 2.29%, and reported an ROE of 16.2%. On 5 October, VIB completed a 3-year syndicated loan worth USD 285 million from nine financial institutions, at a cost of capital about 30 basis points lower than its previous syndicated loan.
- Robinhood’s Tenev warns US tokenization uncertainty deters ‘serious assets’
Robinhood CEO Vlad Tenev says uncertainty over how long US tokenization rules will last could keep investors from putting substantial assets into tokenized markets, even though the SEC has opened a temporary path through an innovation exemption. He says further rulemaking or legislation is needed to provide longer-term certainty, and Binance Research projects the tokenized equities market could reach $349 billion by 2030 under its base case, from $4.43 billion as of Sept. 15. In the third quarter, Robinhood's crypto revenue fell 55% year on year to $120 million and crypto notional trading volume fell 38% to $50 billion. By contrast, event-contract revenue rose sixfold to $173 million, and total net revenue rose 12% to a record $1.42 billion, below analyst expectations. Adjusted EPS was $0.60, missing estimates by 4 cents.
- Is Anthropic a SaaS Stock? Here's How It Stacks Up With the Other Top Software Players
Anthropic has released its S-1 filing ahead of what could be the biggest IPO ever, targeting a valuation of around $2 trillion. Although it is often called an AI lab, the company shares several traits with SaaS stocks: it sells Claude and Claude Code through monthly subscriptions and reports metrics such as customers by annual recurring revenue (ARR), with more than 11,900 customers at $10,000 or more ARR as of the end of the third quarter. Sales, marketing and partnerships took less than 20% of revenue in the first half of 2026, and the company had 5,300 employees at the end of the third quarter, far fewer than Salesforce's roughly 83,000. Based on third-quarter revenue of $16.8 billion (annualised to $67 billion), the $2 trillion valuation implies a price-to-sales ratio of around 30, close to Datadog at 25.4 and Snowflake at 21.9. The article says this looks relatively low given sequential revenue growth of nearly 50% and adjusted profitability, though the stock carries risks such as large cloud spending commitments.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.